A number of studies have addressed the safety of vascular endothelial growth factor (VEGF) inhibition for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) [1–3], and retinal vein occlusion (RVO) [4, 5]. The gene discussed is VEGFA; the disease is retinal vein occlusion.